Video

ORLANDO – Primary care physicians need to be on the front line of pain care, explained Dr. Paul J. Christo.

The most important reason is the sheer volume of individuals with chronic pain, according to Dr. Christo, associate professor of anesthesiology at Johns Hopkins University, Baltimore.

In an interview at a meeting held by the American Pain Society and Global Academy for Medical Education, Dr. Christo discussed the trends driving pain cases into primary care offices and how primary care physicians can manage those cases in a busy practice.

Dr. Christo reported financial relationships with Algiatry, Egalet, Golin Harris, Purdue, Rahm, and Trevena. Global Academy and this news organization are owned the same company.

ORLANDO – Primary care physicians need to be on the front line of pain care, explained Dr. Paul J. Christo.

The most important reason is the sheer volume of individuals with chronic pain, according to Dr. Christo, associate professor of anesthesiology at Johns Hopkins University, Baltimore.

In an interview at a meeting held by the American Pain Society and Global Academy for Medical Education, Dr. Christo discussed the trends driving pain cases into primary care offices and how primary care physicians can manage those cases in a busy practice.

Dr. Christo reported financial relationships with Algiatry, Egalet, Golin Harris, Purdue, Rahm, and Trevena. Global Academy and this news organization are owned the same company.

ORLANDO – Primary care physicians need to be on the front line of pain care, explained Dr. Paul J. Christo.

The most important reason is the sheer volume of individuals with chronic pain, according to Dr. Christo, associate professor of anesthesiology at Johns Hopkins University, Baltimore.

In an interview at a meeting held by the American Pain Society and Global Academy for Medical Education, Dr. Christo discussed the trends driving pain cases into primary care offices and how primary care physicians can manage those cases in a busy practice.

Dr. Christo reported financial relationships with Algiatry, Egalet, Golin Harris, Purdue, Rahm, and Trevena. Global Academy and this news organization are owned the same company.

Concern among the medical community exists regarding risks and benefits of prostate cancer screening in patients aged ≥ 65 years. The clear objective of early detection is usually to prolong life and independence and improve quality of life. This involves a comprehensive risk assessment to be conducted as well as educating the patient about prostate cancer before incorporating their feelings into treatment decisions.

“Even though, quite frequently, men 65 and older are being screened for prostate cancer,” noted Wayne B. Harris, MD, “it is quite infrequent that they are actually diagnosed or treated for prostate cancer.” Dr. Harris also noted that 2 of 3 veterans aged ≥ 65 years who undergo PSA screening will never have a prostate biopsy or receive treatment for prostate cancer.

Concern among the medical community exists regarding risks and benefits of prostate cancer screening in patients aged ≥ 65 years. The clear objective of early detection is usually to prolong life and independence and improve quality of life. This involves a comprehensive risk assessment to be conducted as well as educating the patient about prostate cancer before incorporating their feelings into treatment decisions.

“Even though, quite frequently, men 65 and older are being screened for prostate cancer,” noted Wayne B. Harris, MD, “it is quite infrequent that they are actually diagnosed or treated for prostate cancer.” Dr. Harris also noted that 2 of 3 veterans aged ≥ 65 years who undergo PSA screening will never have a prostate biopsy or receive treatment for prostate cancer.

Concern among the medical community exists regarding risks and benefits of prostate cancer screening in patients aged ≥ 65 years. The clear objective of early detection is usually to prolong life and independence and improve quality of life. This involves a comprehensive risk assessment to be conducted as well as educating the patient about prostate cancer before incorporating their feelings into treatment decisions.

“Even though, quite frequently, men 65 and older are being screened for prostate cancer,” noted Wayne B. Harris, MD, “it is quite infrequent that they are actually diagnosed or treated for prostate cancer.” Dr. Harris also noted that 2 of 3 veterans aged ≥ 65 years who undergo PSA screening will never have a prostate biopsy or receive treatment for prostate cancer.

ORLANDO – Address chronic pain with multiple modalities individualized by patient clinical profile, said Dr. Charles E. Argoff, professor of neurology and director of the Comprehensive Pain Center at Albany (N.Y.) Medical Center, in a video interview.

The neuroplastic changes that take place in the nervous system following a lesion or injury may respond in an aberrant manner in some patients, triggering chronic pain, and the clinician’s job is to find the right mix of interventions – pharmacologic, behavioral, and/or surgical – that best matches the patient’s clinical profile, he said at the meeting held by the American Pain Society and Global Academy for Medical Education. Global Academy and this news organization are owned by the same company.

Dr. Argoff reported financial relationships with Allergan, AstraZeneca, Depomed, Eli Lilly, Endo Pharmaceuticals, Forest Laboratories, Millennium Laboratories, Nektar Therapeutics, Pfizer, Xenoport, and Zogenix.

ORLANDO – Address chronic pain with multiple modalities individualized by patient clinical profile, said Dr. Charles E. Argoff, professor of neurology and director of the Comprehensive Pain Center at Albany (N.Y.) Medical Center, in a video interview.

The neuroplastic changes that take place in the nervous system following a lesion or injury may respond in an aberrant manner in some patients, triggering chronic pain, and the clinician’s job is to find the right mix of interventions – pharmacologic, behavioral, and/or surgical – that best matches the patient’s clinical profile, he said at the meeting held by the American Pain Society and Global Academy for Medical Education. Global Academy and this news organization are owned by the same company.

Dr. Argoff reported financial relationships with Allergan, AstraZeneca, Depomed, Eli Lilly, Endo Pharmaceuticals, Forest Laboratories, Millennium Laboratories, Nektar Therapeutics, Pfizer, Xenoport, and Zogenix.

ORLANDO – Address chronic pain with multiple modalities individualized by patient clinical profile, said Dr. Charles E. Argoff, professor of neurology and director of the Comprehensive Pain Center at Albany (N.Y.) Medical Center, in a video interview.

The neuroplastic changes that take place in the nervous system following a lesion or injury may respond in an aberrant manner in some patients, triggering chronic pain, and the clinician’s job is to find the right mix of interventions – pharmacologic, behavioral, and/or surgical – that best matches the patient’s clinical profile, he said at the meeting held by the American Pain Society and Global Academy for Medical Education. Global Academy and this news organization are owned by the same company.

Dr. Argoff reported financial relationships with Allergan, AstraZeneca, Depomed, Eli Lilly, Endo Pharmaceuticals, Forest Laboratories, Millennium Laboratories, Nektar Therapeutics, Pfizer, Xenoport, and Zogenix.